For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| SPD503 Alone | Single 4 mg dose of extended-release Guanfacine HCl | None | None | 0 | 40 | 9 | 40 | View |
| Vyvanse Alone | Single 50 mg dose | None | None | 0 | 41 | 6 | 41 | View |
| SPD503 + Vyvanse | SPD503 (single 4 mg dose) + Vyvanse (single 50 mg dose) coadministered | None | None | 0 | 41 | 6 | 41 | View |